Abiraterone Acetate Trial in African American Prostate Cancer Patients
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a pilot study of abiraterone acetate in African American/Black patients with
castration-resistant prostate cancer. The primary objective is to determine the correlation
between germline polymorphisms and antitumor activity (as defined by a decline in PSA of ≥
30%) in African American patients with castration-resistant prostate cancer treated with
abiraterone acetate. Patients will receive abiraterone acetate until the time of disease
progression, in the absence of prohibitive toxicities. Patients will be followed for disease
progression and survival.